Capricor Therapeutics (CAPR) Stock Price, News & Analysis

Company Overview

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Key Stats

• Today's Range: $9.99 to $11.58
• 50-Day Range: $6.35 to $14.23
• 52-Week Range: $3.52 to $23.40
• Volume: 2.64 million shs
• Average Volume: 1.97 million shs
• Market Capitalization: $509.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.75
• Consensus Rating: Buy

Capricor Therapeutics Stock Analysis - MarketRank™

Capricor Therapeutics scored higher than 64% of companies evaluated by MarketBeat, and ranked 373rd out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.6 / 5
• Analyst Rating: Buy

Consensus Rating

Capricor Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Capricor Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Capricor Therapeutics are expected to grow in the coming year, from ($1.21) to ($0.75) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Capricor Therapeutics is -7.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Capricor Therapeutics is -7.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Capricor Therapeutics has a P/B Ratio of 3.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

24.97% of the float of Capricor Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Capricor Therapeutics has a short interest ratio ("days to cover") of 4.

Change versus previous month

Short interest in Capricor Therapeutics has recently decreased by 7.85%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Capricor Therapeutics does not currently pay a dividend.

Dividend Growth

Capricor Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

24.97% of the float of Capricor Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Capricor Therapeutics has a short interest ratio ("days to cover") of 4.

Change versus previous month

Short interest in Capricor Therapeutics has recently decreased by 7.85%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.26

News Sentiment

Capricor Therapeutics has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.94 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 24 news articles for Capricor Therapeutics this week, compared to 6 articles on an average week.

Search Interest

Only 1 people have searched for CAPR on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

Only 6 people have added Capricor Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Capricor Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.50% of the stock of Capricor Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 21.68% of the stock of Capricor Therapeutics is held by institutions.

CAPR Stock Analysis - Frequently Asked Questions

How have CAPR shares performed this year?

Capricor Therapeutics' stock was trading at $13.80 on January 1st, 2025. Since then, CAPR shares have decreased by 19.2% and is now trading at $11.15.
View the best growth stocks for 2025 here.

How were Capricor Therapeutics' earnings last quarter?

Capricor Therapeutics, Inc. (NASDAQ:CAPR) issued its quarterly earnings data on Tuesday, May, 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by $0.20. The biotechnology company earned $2.73 million during the quarter, compared to analyst estimates of $3.16 million. Capricor Therapeutics had a negative trailing twelve-month return on equity of 62.42% and a negative net margin of 181.71%.
Read the conference call transcript.

Who are Capricor Therapeutics' major shareholders?

Capricor Therapeutics' top institutional shareholders include Vanguard Group Inc. (4.96%), Woodline Partners LP (1.60%), Octagon Capital Advisors LP (0.99%) and Goldman Sachs Group Inc. (0.90%). Insiders that own company stock include Shinyaku Co Ltd Nippon, David B Musket, Paul Gisbert Auwaerter and Xavier Avat.
View institutional ownership trends.

How do I buy shares of Capricor Therapeutics?

Shares of CAPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Capricor Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Capricor Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Moderna (MRNA), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 6/28/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CAPR
• CIK: 1133869
• Web: www.capricor.com
• Phone: 310-358-3200
• Fax: 415-875-7075
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $33.75
• High Stock Price Target: $77.00
• Low Stock Price Target: $21.00
• Potential Upside/Downside: +202.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.13
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$40.47 million
• Net Margins: -181.71%
• Pretax Margin: -317.12%
• Return on Equity: -62.42%
• Return on Assets: -48.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.55
• Quick Ratio: 6.55

Sales & Book Value

• Annual Sales: $22.27 million
• Price / Sales: 22.87
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.20 per share
• Price / Book: 3.48

Miscellaneous

• Outstanding Shares: 45,680,000
• Free Float: 40,881,000
• Market Cap: $509.33 million
• Optionable: Optionable
• Beta: 0.84